• DOI:10.2165/00002018-199819010-00002
Corpus ID: 9632549

Safety of Selegiline (Deprenyl) in the Treatment of Parkinson’s Disease

@article{Heinonen1998SafetyOS,
  title={Safety of Selegiline (Deprenyl) in the Treatment of Parkinson’s Disease},
  author={E. Heinonen and V. Myllyl{\"a}},
  journal={Drug Safety},
  year={1998},
  volume={19},
  pages={11-22}
}

E. Heinonen, V. Myllylä

Published 1998

Medicine

Drug Safety

Selegiline (deprenyl), a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B) is widely used in the treatment of Parkinson’s disease. As the first MAO-B inhibitor approved for the treatment of Parkinson’s disease, concerns were raised about the safety of the drug based on the adverse effect profiles of older, nonselective MAO inhibitors. Unlike the nonselective MAO inhibitors, selegiline does not significantly potentiate tyramine-induced hypertension (the ‘cheese effect’) at… CONTINUE READING

View on Springer

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed